Following the acquisition GlycoVaxyn by GSK in February 2015, GSK commissioned the management team to create a new company, LimmaTech Biologics AG in Schlieren near Zurich, which acquired GlycoVaxyn’ s operational research business . LimmaTech Biologics is not a GSK?owned company. GSK and LimmaTech Biologics have signed a research agreement with a minimum term of five years to allow LimmaTech Biologics to develop novel bioconjugate antigen?based vaccines exclusively for GSK. VISCHER assisted LimmaTech Biologics starting at foundation and in the collaboration agreement with GSK. The team at VISCHER is led by Matthias Staehelin (Partner) with Christian Wyss (Partner), Dania Salvisberg-Schneider (Associate), Moritz Jäggy (Associate), all Corporate and Nadia Tarolli (Partner, Tax).